Background: Connecting HIV+ individuals to treatment programs and sustaining effective antiretroviral therapy (ART) is a challenge in developing countries. The implications of addressing patient linkage and retention are not only partially characterized. We use the national coverage of data on HIV care in Rwanda to estimate the epidemiologic benefits and cost-effectiveness of improving the HIV care cascade.
Methods: We parameterized an HIV disease and transmission simulation model to reflect the epidemic in Rwanda using age-structured prevalence and detailed information on ART program. The care cascade was modeled as a time-dependent process of patient loss between diagnosis and initial staging, staging and ART initiation, and loss after ART initiation. Costs were obtained from a top-down accounting of HIV testing, treatment, and laboratory monitoring in Rwanda. Alternative scenarios included improving HIV testing to 100% of the population, perfect linkage from testing to staging, and reduction of pre-ART and post-ART patient leakage to 0%. In addition, we simulated a strategy of immediate treatment among patients linked to care, as opposed to treatment initiation at CD4<350 cells/mm3. Model and parameter uncertainty were estimated using Monte Carlo and probabilistic simulations.
Results: We calibrated the model to Rwanda’s adult HIV prevalence between 2004 and 2013, a drop from 3.6% to 2.8%. Incidence reduction was greatest under a scenario of combined perfect system performance, including immediate ART initiation (49% reduction in 10 years (uncertainty bounds 39-60%)), followed by immediate treatment initiation (36%, 28-43%) and reduction of post-ART patient loss (14%, 5-22%). Using a unit-cost approach to estimate the total costs of scaling up HIV treatment and services, we estimate that adopting immediate ART initiation will cost approximately $120 million additional to the status quo (discounted at 3% annually). The incremental cost-effectiveness of immediate ART initiation was estimated at $1,094 per life-year gained (556-1922), and that of a perfect system performance, including immediate ART initiation was $1,803 (1122-2912) per life-year gained. No other scenario was cost-effective.
Conclusions: Using national data on ART care and treatment in Rwanda, we demonstrate that the greatest epidemiologic benefits are likely to result from immediate ART initiation. While the budgetary implications of immediate initiation are large, this approach is cost-effective in Rwanda by traditional standards.